Alga Biosciences vs Altria

Side-by-side comparison of AI visibility scores, market position, and capabilities

Altria leads in AI visibility (90 vs 43)

Alga Biosciences

EmergingClimate & Energy

Agricultural Climate Solutions

Alga Biosciences is a biotech company engineering methane-reducing feed additives derived from seaweed to cut livestock methane emissions, addressing one of agriculture's largest climate impacts. HQ: San Francisco.

AI VisibilityBeta
Overall Score
C43
Category Rank
#1 of 1
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
50
Perplexity
43
Gemini
47

About

Alga Biosciences is a climate biotechnology company developing seaweed-based feed supplements that reduce methane emissions from cattle and other ruminant livestock. Cattle and sheep emit methane through enteric fermentation — a digestive process where microbes in the rumen produce methane as a byproduct of breaking down plant material. Enteric fermentation from livestock accounts for approximately 4% of global greenhouse gas emissions (as methane is ~80x more potent than CO2 over 20 years), making it one of the largest targets for agricultural decarbonization.

Full profile

Altria

LeaderConsumer Goods

Enterprise

Richmond VA tobacco and nicotine (NYSE: MO) ~$9.7B net revenue FY2024; Marlboro 40%+ US cigarette share, on! oral pouch competing with Zyn, 50%+ operating margins, ABI stake, competing with Reynolds/BAT.

AI VisibilityBeta
Overall Score
A90
Category Rank
#83 of 290
AI Consensus
58%
Trend
stable
Per Platform
ChatGPT
84
Perplexity
97
Gemini
99

About

Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and selling cigarettes (Marlboro — the best-selling cigarette brand in the United States), smokeless tobacco (Copenhagen, Skoal, Red Seal, Husky chewing tobacco/moist snuff brands), oral nicotine pouches (on! brand), and maintaining a 10.7% ownership stake in Anheuser-Busch InBev (SABMiller acquisition consideration shares) and a 35% stake in JUUL Labs (vaping — original $12.8B investment written down to minimal value following JUUL's regulatory and litigation difficulties) through approximately 5,500 employees. In fiscal year 2024, Altria reported revenues of approximately $20.6 billion (net revenues after excise taxes approximately $9.7 billion), with the cigarette segment (Marlboro generating 40%+ US cigarette market share) contributing the majority of operating income at 50%+ adjusted operating margins — the highest margins in the consumer staples sector reflecting cigarettes' inelastic demand and regulated market structure. CEO Billy Gifford has pivoted Altria's strategy from cigarettes toward smoke-free nicotine products: the on! oral nicotine pouch (acquired full ownership of Helix Innovations in 2023, rebranding as on! to compete with Swedish Match Zyn, the dominant US oral nicotine pouch brand) represents Altria's primary nicotine product diversification vehicle as cigarette volume declines 7-8% annually through consumer quit rates and secular health awareness trends.

Full profile

AI Visibility Head-to-Head

43
Overall Score
90
#1
Category Rank
#83
80
AI Consensus
58
stable
Trend
stable
50
ChatGPT
84
43
Perplexity
97
47
Gemini
99
46
Claude
86
51
Grok
87

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.